Omeros provides update on zaltenibart trial
Omeros (OMER) reported that clinical trial site activation for enrollment is underway for the company’s Phase 3 program evaluating zaltenibart ...
Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program
Omeros Corporation (Nasdaq: OMER) today reported that clinical trial site activation for enrollment is underway for the ...
The American Journal of Managed Care8d
FDA Approves Expanded Indication of Eculizumab for Pediatric Generalized Myasthenia Gravis
The FDA first approved eculizumab for use in adult patients with generalized myasthenia gravis in 2017, before expanding the ...
Healio11d
FDA approves Soliris for patients aged 6 years and up with generalized myasthenia gravis
The FDA has approved an expanded indication of Soliris, an IV-administered monoclonal antibody for patients aged 6 years and ...
manilatimes13d
Sezzle Announces Six-for-One Stock Split and $50 Million Stock Repurchase Program
Minneapolis, MN, March 10, 2025 (GLOBE NEWSWIRE) -- Sezzle Inc. (NASDAQ: SEZL,) (Sezzle or Company) // Purpose-driven digital payment platform, Sezzle, today announced that the Company's Board of ...
The Bakersfield Californian13d
FDA Approves Expanded Use of Eculizumab (Soliris) for Pediatric Myasthenia Gravis, Bringing New ...
The Muscular Dystrophy Association (MDA) welcomes the U.S. Food and Drug Administration (FDA) approval of the expanded indication of Alexion/AstraZeneca’s eculizumab ( ...
Business Insider13d
FDA Approves Expanded Use of Eculizumab (Soliris) for Pediatric Myasthenia Gravis, Bringing New Treatment Options for Children
New York, March 10, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) welcomes the U.S. Food and Drug Administration (FDA) approval of the expanded indication of Alexion/AstraZeneca’s ...
Frontiers16d
The treatment of autoimmune hemolytic anemia with complement inhibitor iptacopan: a case report
Plasma cell-targeted therapies: Proteasome inhibitor bortezomib. Complement inhibitors: C5 inhibitor eculizumab. Phagocytosis inhibitors: Fostamatinib, sollepineib, and nipocalimab. Among these, ...
contemporarypediatrics24d
FDA expands label for Odactra dust mite allergen tablet to children 5-11 years
The expanded indication now includes children aged 5 through 11 years, in addition to patients aged 12 to 65 years. On February 28, 2025, the FDA approved an expanded indication for ALK's House Dust ...
Indiatimes25d
Is your urine color hiding a dangerous disease? Uncovering PNH
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disease that affects red blood cells, causing symptoms like dark urine, fatigue, and unexplained bruising. Early diagnosis is challenging due to ...